Nationwide survey of extended newborn screening by tandem mass spectrometry in Taiwan

In Taiwan, during the period March 2000 to June 2009, 1,495,132 neonates were screened for phenylketonuria (PKU) and homocystinuria (HCU), and 1,321,123 neonates were screened for maple syrup urine disease (MSUD), methylmalonic academia (MMA), medium-chain acyl-coenzyme A (CoA) dehydrogenase (MCAD) deficiency, isovaleric academia (IVA), and glutaric aciduria type 1 (GA-1) using tandem mass spectrometry (MS/MS). In a pilot study, 592,717 neonates were screened for citrullinemia, 3-methylcrotonyl-CoA carboxylase deficiency (3-MCC) and other fatty acid oxidation defects in the MS/MS newborn screening. A total of 170 newborns and four mothers were confirmed to have inborn errors of metabolism. The overall incidence was approximately 1/5,882 (1/6,219 without mothers). The most common inborn errors were defects of phenylalanine metabolism [five classic PKU, 20 mild PKU, 40 mild hyperphenylalaninemia (HPA), and 13 6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency]. MSUD was the second most common amino acidopathy and, significantly, most MSUD patients (10/13) belonged to the Austronesian aboriginal tribes of southern Taiwan. The most frequently detected among organic acid disorders was 3-MCC deficiency (14 newborns and four mothers). GA-1 and MMA were the second most common organic acid disorders (13 and 13 newborns, respectively). In fatty acid disorders, five carnitine transport defect (CTD), five short-chain acyl-CoA dehydrogenase deficiency (SCAD), and two medium-chain acyl-CoA dehydrogenase (MCAD) deficiency were confirmed. This is the largest case of MS/MS newborn screening in an East-Asian population to date. We hereby report the incidences and outcomes of metabolic inborn error diseases found in our nationwide MS/MS newborn screening program.

[1]  P. McDonough.  Newborn Screening Fact Sheets , 1989, Pediatrics.

[2]  E. Naughten,et al.  Newborn screening for homocystinuria: Irish and world experience , 1998, European Journal of Pediatrics.

[3]  K. Tokunaga,et al.  Heterogeneity of Taiwan's indigenous population: possible relation to prehistoric Mongoloid dispersals. , 2000, Tissue antigens.

[4]  S. Chiang,et al.  Tetrahydrobiopterin-deficient hyperphenylalaninemia in the Chinese. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[5]  D. Millington,et al.  Glutaric acidemia, type I, missed by newborn screening in an infant with dystonia following promethazine administration. , 2001, Pediatrics.

[6]  W. Hwu,et al.  A founder mutation (R254X) of SLC22A5 (OCTN2) in Chinese primary carnitine deficiency patients , 2002, Human mutation.

[7]  Hsiu-Fen Lee,et al.  Maple syrup urine disease in the Austronesian aboriginal tribe Paiwan of Taiwan: a novel DBT (E2) gene 4.7 kb founder deletion caused by a nonhomologous recombination between LINE-1 and Alu and the carrier-frequency determination , 2003, European Journal of Human Genetics.

[8]  Martin Lindner,et al.  Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications. , 2003, Pediatrics.

[9]  R. Wanders,et al.  MS/MS-based newborn and family screening detects asymptomatic patients with very-long-chain acyl-CoA dehydrogenase deficiency. , 2003, The Journal of pediatrics.

[10]  Y. Chien,et al.  Mutation spectrum in Taiwanese patients with phenylalanine hydroxylase deficiency and a founder effect for the R241C mutation , 2004, Human mutation.

[11]  K. Hsiao,et al.  Adult-onset type II citrullinemia and idiopathic neonatal hepatitis caused by citrin deficiency: involvement of the aspartate glutamate carrier for urea synthesis and maintenance of the urea cycle. , 2004, Molecular genetics and metabolism.

[12]  M. Matsuo,et al.  A novel deletion creating a new terminal exon of the dihydrolipoyl transacylase gene is a founder mutation of Filipino maple syrup urine disease. , 2004, Molecular genetics and metabolism.

[13]  D. L. Norwood,et al.  Tandem mass spectrometry: A new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism , 1990, Journal of Inherited Metabolic Disease.

[14]  D. Marsden,et al.  Normal acylcarnitine levels during confirmation of abnormal newborn screening in long-chain fatty acid oxidation defects , 2005, Journal of Inherited Metabolic Disease.

[15]  B. Andresen,et al.  VLCAD deficiency: pitfalls in newborn screening and confirmation of diagnosis by mutation analysis. , 2006, Molecular genetics and metabolism.

[16]  M. Durán,et al.  Guideline for the diagnosis and management of glutaryl-CoA dehydrogenase deficiency (glutaric aciduria type I) , 2007, Journal of Inherited Metabolic Disease.

[17]  D. Millington,et al.  The tandem mass spectrometry newborn screening experience in North Carolina: 1997–2005 , 2006, Journal of Inherited Metabolic Disease.

[18]  D. Niu,et al.  Corneal lesion as the initial manifestation of tyrosinemia type II. , 2006, Journal of the Chinese Medical Association : JCMA.

[19]  K. Hsiao,et al.  Long-term follow-up of Chinese patients who received delayed treatment for 6-pyruvoyl-tetrahydropterin synthase deficiency. , 2006, Molecular genetics and metabolism.

[20]  R. Wanders,et al.  Pitfalls of neonatal screening for very-long-chain acyl-CoA dehydrogenase deficiency using tandem mass spectrometry. , 2006, The Journal of pediatrics.

[21]  D. Niu,et al.  Lenticular subluxation in a patient with homocystinuria undetected by neonatal screening. , 2007, Journal of the Chinese Medical Association : JCMA.

[22]  B. Casetta,et al.  Progress in expanded newborn screening for metabolic conditions by LC-MS/MS in Tuscany: Update on methods to reduce false tests , 2008, Journal of Inherited Metabolic Disease.

[23]  K. Hsiao,et al.  Long-term follow-up of Taiwanese Chinese patients treated early for 6-pyruvoyl-tetrahydropterin synthase deficiency. , 2008, Archives of neurology.

[24]  Y. Chien,et al.  Brain damage by mild metabolic derangements in methylmalonic acidemia. , 2008, Pediatric neurology.

[25]  C. Padilla,et al.  Maple syrup urine disease (MSUD)—Clinical profile of 47 Filipino patients , 2008, Journal of Inherited Metabolic Disease.

[26]  K. Hsiao,et al.  Growth Hormone Therapy in Neonatal Patients With Methylmalonic Acidemia , 2009, Journal of the Chinese Medical Association : JCMA.

[27]  A. Bener,et al.  Newborn population screening for classic homocystinuria by determination of total homocysteine from Guthrie cards. , 2010, The Journal of pediatrics.

[28]  Y. Chien,et al.  Diagnoses of newborns and mothers with carnitine uptake defects through newborn screening. , 2010, Molecular genetics and metabolism.